SCHEMBL4473556

SCHEMBL4473556

COc1cc2c(Oc3ccc(NC(=O)NC4CCCC(C)(C)C4)c(F)c3)ccnc2cc1OCCN1CC(C)OC(C)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.53
PDGFRA P16234 5/20 0.53
KIT P10721 4/20 0.53
AXL P30530 2/20 0.53
FGFR2 P21802 2/20 0.53
MET P08581 6/20 0.50
EGFR P00533 2/20 0.50
RET P07949 2/20 0.50
IGF1R P08069 1/20 0.50
SRC P12931 1/20 0.50
MST1R Q04912 1/20 0.50
FGFR4 P22455 2/20 0.49
HDAC1 Q13547 1/20 0.47
FLT1 P17948 4/20 0.45
FLT4 P35916 4/20 0.45
RIPK2 O43353 1/20 0.44
ERN1 O75460 1/20 0.44
STK10 O94804 1/20 0.44
MAP3K6 O95382 1/20 0.44
ABL1 P00519 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487730 0.91 MET (0.58) KDRPDGFRAKITAXLFGFR2
SCHEMBL13936784 0.88 KDR (0.60) KDRPDGFRAKITAXLFGFR2
SCHEMBL4475372 0.88 KDR (0.67) KDRPDGFRAKITAXLFGFR2
SCHEMBL4468859 0.83 KDR (0.57) KDRPDGFRAKITAXLFGFR2
SCHEMBL5090471 0.83 PDGFRA (0.61) KDRPDGFRAKITAXLFGFR2
SCHEMBL4484630 0.82 KDR (0.55) KDRPDGFRAKITAXLFGFR2
SCHEMBL4476901 0.80 FGFR4 (0.67) KDRPDGFRAKITAXLFGFR2
SCHEMBL13937006 0.79 KDR (0.60) KDRPDGFRAKITAXLFGFR2
SCHEMBL4476077 0.79 MET (0.62) KDRPDGFRAKITAXLMET
SCHEMBL4469175 0.79 KDR (0.55) KDRPDGFRAKITAXLFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 KDR 211/4885PDGFRA 372/4885KIT 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.